There's been an alarming increase of respiratory and gastrointestinal viruses in the United States lately, causing anxiety about a so-called "quad-demic". According to surveillance reports, influenza, COVID-19, RSV and norovirus are at very high levels everywhere. While the surge aligns with patterns typical for this season, several epidemiologists view simultaneous infections of such proportions to pose risks not only to individual healthcare but public health.

The incidence of the quad-demic should vary with seasonal patterns, vaccination rates, and public health interventions. Each virus alone is relatively easy to manage; however, the effect of all together could lead to overburdening of health care facilities and increase risks for those at higher risk. Continuing surveillance, early testing, and proactive prevention measures will play an important role in the control of these infections going forward.

While the term "quad-demic" sounds daunting, it must be taken into perspective. For years, we have had all these viruses together, and we have the capabilities to mitigate some of the risk. Vaccination, proper hygiene and using common sense helps individuals get through the season unscathed. Is the quad-demic a permanent fixture or just another seasonal wave? Let's break this down.

What is the Quad-demic?

Typically, flu, COVID-19, and RSV have been the primary culprits behind seasonal respiratory infections. However, norovirus, a highly contagious stomach bug, has emerged as a fourth significant player, inducing fears of a more severe and widespread viral outbreak. According to the Centers for Disease Control and Prevention (CDC), the U.S. recorded nearly 500 norovirus outbreaks between August and December 2023, a substantial rise from the previous year’s numbers.

While the term "quad-demic" may sound ominous, the seriousness and consequences of such infections should be weighed in light of the U.S. healthcare system's experience with managing viral surges since the start of the COVID-19 pandemic.

1. Influenza (Flu)

Flu continues to be one of the most common and alarming seasonal illnesses. In the period spanning from 2023 to 2024, there were approximately 40 million cases of flu, and thousands of hospitalizations along with reported 47 deaths have been reported this season. Flu symptoms include fever, chills, cough, sore throat, muscle pain, and fatigue, with most recovering within a week or two but risky factors for severe illness effects occur in young children, elderly, and people with chronic conditions.

2. Covid-19

Despite its reduction from the first pandemic peak, COVID-19 is still rampant. The CDC estimates that alone between October and December 2023, there were between 2.7 and 5 million cases in the U.S. Hospitalization has increased by cities such as Los Angeles, Chicago, and New York. Symptoms are closely similar to the flu, fever, cough, and fatigue but uniquely presents in some cases as loss of taste and smell.

3. RSV

RSV is the most common cause of lower respiratory infections in infants, older adults, and immunocompromised individuals. While RSV peaked late in 2023 and early 2024, it continues to be a threat because it can lead to bronchiolitis and pneumonia. It is very similar to the common cold, presenting with symptoms such as congestion, runny nose, coughing, and fever, which can make it difficult to differentiate from flu or COVID-19 without testing.

4. Norovirus

Norovirus, also called the "stomach flu," is a highly contagious infection of the gastrointestinal tract, not a respiratory virus. It transmits quickly from contaminated food and water and contact with contaminated surfaces, causing such symptoms as diarrhea, vomiting, nausea, and stomach pain. Cases have shot up, the CDC said Monday, with reports of outbreaks surging compared with last year.

Is There a Challenge In Diagnosis Due to Overlapping Symptoms?

The greatest challenge during the quad-demic is how the four viruses are alike and thus make identification very hard with no testing applied. Most cases present symptoms common to all viruses: fever, tiredness, body pains, and respiratory, which includes coughing and congestions for influenza, COVID-19, and RSV; the other would be norovirus symptoms as nausea and vomiting can appear even in extreme influenza and COVID-19. This overlap increases the risk of misdiagnosis and delayed treatment, hence the need for early testing and proper medical guidance.

Also Read: Is US Preparing For A Quad- demic 2025?

Effective Prevention Strategies That Work

The best defense against these viruses is a combination of vaccines, hygiene, and lifestyle precautions. While lifestyle modifications are highlighted as part of the constant need to eat healthy, ensure daily movement and drinking adequate amount of fluids. There is a sure short two preventive strategies that are effective:

Vaccination

• Flu vaccine: Annual flu shots reduce the severity of infection, allergic flare ups and hospitalizations.
• COVID-19 vaccine: Though COVID-19 cases have declined, vaccination remains critical in preventing severe outcomes.
• RSV vaccine: Available for those aged 60 years and older, especially those with underlying conditions.
• Norovirus vaccine: No vaccine is yet available, but mRNA vaccine research is in progress.

Hygiene and Sanitation

• Washing hands frequently with soap and water for at least 20 seconds, especially after public exposure.
• Disinfect frequently touched surfaces regularly, use sanitiser when outside.
• Avoid close contact with infected people and wear masks.

Do You Need To Wear A Mask All The Time?

While debates on masked wear continue on, experts on mask-wear affirm that this does not only have a historical precedent but works towards reducing airborne viruses spreading within the environments. Hospitals, though, ensure masking in key sections of themselves. Publicized mask-wear remains a discretion, though massing indoors still goes a longer way in cases like peak flu seasons.

If you notice the symptoms of these viruses, then it's best to be confined at home and avoid having face-to-face interaction with others and seek immediate attention from your physician if your condition worsens. Quarantining for some days can decrease the spread of infection.

As we move into the first half of 2025 and beyond, staying informed and proactive is the best strategy for maintaining health and avoiding unnecessary panic. The key takeaway? Stay vigilant, but don’t be alarmed—these viruses are here, but so are the means to fight them.

Heart disease is the leading cause of death globally and in the United States, claiming roughly 17.9 to 19.8 million lives each year. Cardiovascular diseases such as heart attacks and stroke account for roughly one in every three deaths worldwide.

To date, there is no single vaccine that cures or prevents heart disease itself. However, researchers from the University of Oxford found that the currently available shingles vaccine, Shingrix, may significantly lower the risk of heart attack and stroke.

Published in the journal Nature Medicine, the observational research, based on health records of 70,000 people in the US, showed that people who received the recombinant shingles vaccine were less likely than unvaccinated people to have heart attacks, strokes or heart failure.

“Given the global burden of cardiovascular disease, these findings, if confirmed in clinical trials and mechanistic studies, would have important implications for public health,” the researchers said in the paper.

Also read: Unapproved Weight-Loss Drug Caused Hospitalisations In Ireland: What Is Retatrutide & Why Is It Risky?

What Did The Study Find?

The Oxford researchers tracked the health records of 70,000 adults aged 60 and over for seven years after vaccination, which involved an initial dose and a booster.

Shingrix was associated with a 12% reduction in cardiovascular events — including heart attacks, heart failure and stroke — in the first three and a half years after vaccination.

By the end of the follow-up, the vaccine was associated with a 4% lower risk of cardiovascular disease.

While this represents a small change in absolute risk, the overall impact could be significant.

“If confirmed in a randomized controlled trial, the effect of Shingrix would be equivalent to antihypertensives,” co-author Maxime Taquet, associate professor of psychiatry at the University of Oxford, said at a media briefing.

What Is Shingrix?

Read More: Tivicay: US FDA Approves Drug to Treat HIV In Newborns

Shingrix is the recombinant herpes zoster (shingles) vaccine. Shingles is a painful, often serious flare-up of the chickenpox virus from childhood. It can cause a rash and nerve pain that may persist for months or years after the rash clears, a complication known as post-herpetic neuralgia.

In 2006, Zostavax became the first vaccine available against shingles and was based on a weakened version of the chickenpox virus. It was succeeded by Shingrix in 2017, a more effective recombinant vaccine that uses newer vaccine technology.

How Could Shingrix Reduce CVD Risk?

Research is ongoing and more definitive evidence is awaited. According to experts, Shingrix may help reduce cardiovascular risk because shingles may increase the risk of heart and vascular diseases.

Separately, the vaccine could be having broader effects on the immune system that suppress inflammatory proteins.

“This study remains observational, even though it’s a natural experiment, and so we are keen to see results from randomized controlled trials. And one of them is underway,” Taquet said, The Guardian was quoted as saying.

More Research Is Needed

“If confirmed, Shingrix could prevent hundreds of thousands of cardiovascular events in the USA alone, and may be the first vaccine that protects the heart and the brain,” Taquet said.

While shingles vaccines are currently offered mainly to middle-aged or older people, others could possibly benefit, too. Taquet said more people should be vaccinated against shingles, STAT News reported.

“If these findings and the findings we provided for dementia help sort of nudge that, then that’s great. And if they are then confirmed in randomized controlled trials, the benefit might be enormous, for the people and for the economy and the health services,” he said.

“If this helps people get the vaccine, then that’s great. But they should get it for the shingles protection in the first instance.”

Ahead of the festive season, the Uttar Pradesh food safety and drug administration have tightened inspections of sweets, dairy products and other food items. According to latest reports, around 490 kg of sweets and 275 kg of paneer destroyed in Bareilly after officials found them unfit for consumption or being stored in unhygienic conditions.

The move comes as demand for sweets, khoya, milk and paneer increases around festivals including Raksha Bandhan, Barawafat (Eid-e-Milad-un-Nabi) and Janmashtami.

490 Kg Of Sweets Destroyed In Bareilly

Four food safety teams conducted raids across Bareilly on August 24. During an inspection at Tirpal Ankur Sweets in Nadausi village, officials found sweets including kalakand, barfi, sohan papdi and rasgullas being prepared, handled, and stored in unhygienic conditions.

Assistant Commissioner (Food) Rahul Singh said samples were collected and sent to a laboratory for testing. Officials destroyed 140 kg of kalakand and 350 kg of barfi, together weighing around 490 kg and estimated to be worth Rs 1.70 lakh.

Samples were also collected from several other sweet shops, including peda, barfi, khoya and laddus. Further action will be taken depending on the laboratory results.

Also read: FSSAI Flags Food Firms For Misleading ‘100%’, ‘Energy Drink’, Immunity Claims

275 Kg Spoiled Paneer Seized And Destroyed

In a separate operation, food safety officials and police intercepted a food transport vehicle which was travelling from Badaun to Bareilly around midnight on August 23.

The team recovered approximately 275 kg of paneer, which officials said was in a highly deteriorated condition. They said it had been emitting a foul odour and had been stored unhygienically.

After collecting a sample, authorities seized and destroyed the entire batch, estimated to be worth around Rs 65,760.

The action comes amid similar food safety drives during festive season at other places in Uttar Pradesh.

In Noida, authorities recently seized and destroyed around 300 kg of paneer, citing it was unfit for consumption. Multiple samples of paneer, curd and sweets were sent for laboratory testing.

Also read: FSSAI Orders Halt Of Ghee Sales Amid Adulteration Crackdown: How To Spot Fake Ghee & Its Effects On Your Health

Why Are Unsafe Sweets And Paneer A Health Risk?

Poor hygiene and improper storage of food can allow harmful microorganisms to grow in food, especially in milk-based products like paneer, khoya and other sweets.

Eating contaminated food can cause food poisoning, with symptoms like nausea, vomiting, diarrhoea, abdominal cramps and fever.

In some cases, particularly among young children, older adults and people with weakened immunity, severe infection can lead to dehydration and other serious complications.

Spoiled dairy products can also undergo deterioration on a microbe level, which can produce foul odour and harmful changes in texture and taste. But, appearance, taste or smell alone cannot reliably determine whether food is safe, which is why laboratory testing is important.

Also read: After Diageo, FSSAI Inspects Pernod Ricard Plant, Tests Whisky Samples

How Can Consumers Stay Safe During Festive Season?

As festive demand rises, consumers can reduce their risk by buying sweets and dairy products from licensed, reputable establishments and avoiding products that appear improperly stored or handled.

Fresh dairy-based sweets should be kept under appropriate temperature conditions, while packaged products should be checked for expiry dates, manufacturing details and storage instructions.

This comes amid a broader FSSAI action in which the food safety authority has been tightening rules against food establishments and brands that are in violation due to various misconducts. Recently, it ordered to stop the sale of all variants of ghee manufactured by Daman-based SDP Industries, after laboratory tests found signs of adulteration and violation of food safety standards.

The move came after an inspection conducted on May 19. FSSAI said multiple samples were found adulterated, with laboratory analysis detecting β-sitosterol, a plant sterol that should not be present in genuine ghee. The samples also contained abnormalities in fatty-acid composition.

The food regulator has prohibited the manufacture, storage and sale of the company’s ghee products from its authorised premises until further orders. The products include brands like SHRADDHA, SHREE SARAS and GOKUL.

Irish health authorities are warning people against using retatrutide, an experimental weight-loss drug that has led to multiple cases of hospitalisation after people obtained it outside legitimate clinical trials through unlawful sources.

The warning comes as demand for the drug has grown online, particularly through fitness networks. Despite retatrutide not yet being approved, the masses have been reported to obtain and administer it without medical supervision.

Ireland's Health Service Executive (HSE) has reported patients presenting with serious side effects after taking the drug, including severe vomiting and kidney problems.

Prof Donal O'Shea, HSE Clinical Lead for Obesity, said doctors are seeing patients who have taken retatrutide obtained through unofficial channels.

He said, "Personal trainers who have been giving these jabs give no advice about side effects and how to manage those side effects, leading to real problems".

He also warned that some people are choosing not to disclose this information to the healthcare professionals, which has been making it harder to identify the cause of their symptoms and administer appropriate treatment.

He added, “They are too embarrassed to say they are taking it, leaving us blindfolded when we are trying to come to a conclusion.”

Retatrutide Is An Unapproved Experimental Drug

Also read: Eli Lilly’s Foundayo Launched In UK: Is the GLP-1 Pill Better Than Wegovy, Mounjaro?

Retatrutide is currently being developed by Eli Lilly as a once-weekly injection. Unlike existing GLP-1 medicines like semaglutide and tirzepatide, it simultaneously targets three hormone pathways --- GLP-1, GIP and glucagon. The combination is developed to target appetite, blood sugar regulation and energy metabolism simultaneuously.

Lilly's latest Phase 3 results have shown substantial weight loss. In one trial involving people with obesity or overweight and type 2 diabetes, participants receiving the highest studied dose lost an average of 20.8% of their body weight after 80 weeks.

Another Phase 3 trial reported average weight loss of up to 22.6% after 80 weeks in people with severe obesity and cardiovascular disease.

But promising results do not mean the medicine is ready for unrestricted use, especially before clearance. Its unapproved status indicates that researchers are still examining the drug for potential side-effects and other complications.

Lilly says retatrutide remains an investigational medicine and is legally available only to participants in its clinical trials. The company plans to submit it to the FDA in the first quarter of 2027.

Why Are People Being Hospitalised?

Also read: Ideal Time to Undergo Fertility Treatment for Women Taking GLP-1 Weight-Loss Medications

The Irish warning is particularly concerning as people obtaining retatrutide outside clinical trials may not have an idea about what they are actually injecting, how concentrated the drug is or whether it has been manufactured and stored safely.

Prof O'Shea highlighted cases involving nausea, vomiting and kidney problems. He said, "We had somebody in at the weekend who was getting. Retatrutide twice a week in the gym they go to from their personal trainer and they were in hospital with vomiting and kidney disease. That’s going to happen widescale if people are taking this drug."

Severe vomiting can itself become dangerous because prolonged fluid loss can cause dehydration and acute kidney injury, particularly when someone is unable to keep fluids down.

Growing Concern Of Black Markets

Retatrutide's impressive weight-loss results have fuelled demand for it even though it has not been approved by the FDA. Recent reports spark concerns of a growing black market for the drug, with products being promoted through social media, online sellers, fitness communities and some unregulated clinics. Eli Lilly has taken legal action against companies accused of selling unauthorised retatrutide products.

This is particularly concerning because buyers may mistake a product marketed as “research use only” for a medicine that is safe for human injection. The HSE is urging people not to use retatrutide obtained outside a legitimate clinical trial.

Anyone experiencing severe vomiting, abdominal symptoms, weakness, reduced urination or other concerning symptoms after taking an unapproved weight-loss injection should seek medical attention and tell doctors exactly what they have taken.